FOCL
Neutral signalScored 2026-09-07 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
EDAP TMS S.A. American Depositary Shares
- Nom
- EDAP TMS S.A. American Depositary Shares
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $156.3M
- Employés
- 289
- PDG
- Ryan Rhodes
- Site web
- http://www.focalone.com
- Marché
- —
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 81 000 titres (~384 750,00 $ US)
- Insiders
- Schulz FranWILLSEY LANCERhodes Ryan
- Total bought
-
$384,750
Avg buy (VWAP, 90d window) $4.75 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-14
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-14 | Rhodes Ryan | Buy · P | 21,000 | $4.75 | $99,750 | Form 4 |
| 2026-08-14 | Schulz Fran | Buy · P | 10,000 | $4.75 | $47,500 | Form 4 |
| 2026-08-14 | Shah Sanket | Buy · P | 5,000 | $4.75 | $23,750 | Form 4 |
| 2026-08-14 | WILLSEY LANCE | Buy · P | 50,000 | $4.75 | $237,500 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-07 Drivers: fundamentals. Moteurs : fondamentaux.
Despite a meaningful insider cluster buy signal following strong Q2 results (39% revenue growth), FOCL's underlying financial health is critically weak, with a liquidity score of 25, negative profitability (-41% net…
The first sentence of the analysis written for FOCL on 2026-09-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 1.54 · operating margin -36% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 42.5% | 41.4% | 40.4% | 43.9% | 41.8% | |
| Ebit Margin | -40.2% | -29.6% | -34.3% | -4.6% | 0.7% | |
| Ebitda Margin | -35.4% | -25.5% | -31.1% | -1.6% | 5.1% | |
| Operating Profit Margin | -35.6% | -33.1% | -33.8% | -9.2% | -6.7% | |
| Pretax Profit Margin | -41.4% | -29.9% | -34.7% | -4.9% | 0.6% | |
| Continuous Operations Profit Margin | -41.5% | -29.7% | -35.0% | -5.3% | 1.6% | |
| Net Profit Margin | -41.5% | -29.7% | -35.0% | -5.3% | 1.6% | |
| Bottom Line Profit Margin | -41.5% | -29.7% | -35.0% | -5.3% | 1.6% | |
| Current Ratio | 1.539 | 1.848 | 2.844 | 4.170 | 3.754 | |
| Quick Ratio | 1.194 | 1.359 | 2.296 | 3.627 | 3.336 | |
| Solvency Ratio | -0.435 | -0.380 | -0.544 | -0.043 | 0.100 | |
| Cash Ratio | 0.551 | 0.789 | 1.575 | 2.908 | 2.628 | |
| Price To Earnings Ratio | -4.218 | -4.018 | -8.516 | -118.973 | 232.171 | |
| Price To Earnings Growth Ratio | -0.101 | 0.356 | -0.014 | 0.266 | -1.673 | |
| Forward Price To Earnings Growth Ratio | -0.101 | 0.356 | -0.014 | 0.266 | -1.673 | |
| Price To Earnings Diluted Ratio | -4.218 | -4.018 | -8.516 | -118.973 | 234.902 | |
| Price To Earnings Diluted Growth Ratio | -0.101 | 0.356 | -0.014 | 0.264 | -1.699 | |
| Price To Book Ratio | 6.345 | 1.946 | 3.107 | 4.796 | 3.381 | |
| Price To Sales Ratio | 1.741 | 1.188 | 2.990 | 6.330 | 3.695 | |
| Price To Free Cash Flow Ratio | -5.756 | -5.113 | -11.395 | -95.915 | 40.173 | |
| Price To Operating Cash Flow Ratio | -7.484 | -5.608 | -12.310 | -115.358 | 36.622 | |
| Debt To Assets Ratio | 0.350 | 0.162 | 0.093 | 0.093 | 0.130 | |
| Debt To Equity Ratio | 1.426 | 0.340 | 0.149 | 0.131 | 0.200 | |
| Debt To Capital Ratio | 0.588 | 0.254 | 0.130 | 0.116 | 0.167 | |
| Long Term Debt To Capital Ratio | 0.450 | 0.050 | 0.034 | 0.048 | 0.090 | |
| Financial Leverage Ratio | 4.069 | 2.104 | 1.608 | 1.412 | 1.543 | |
| Working Capital Turnover Ratio | 2.658 | 1.551 | 1.008 | 0.893 | 1.219 | |
| Operating Cash Flow Ratio | -0.443 | -0.375 | -0.521 | -0.137 | 0.257 | |
| Operating Cash Flow Sales Ratio | -0.233 | -0.212 | -0.243 | -0.055 | 0.101 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.300 | 1.097 | 1.080 | 1.203 | 0.912 | |
| Debt Service Coverage Ratio | -2.477 | -1.680 | -3.447 | -0.234 | 0.729 | |
| Interest Coverage Ratio | -31.852 | -89.919 | -88.125 | -30.298 | -57.077 | |
| Short Term Operating Cash Flow Coverage Ratio | -1.760 | -1.445 | -2.777 | -0.650 | 1.230 | |
| Operating Cash Flow Coverage Ratio | -0.595 | -1.019 | -1.693 | -0.317 | 0.462 | |
| Capital Expenditure Coverage Ratio | -3.330 | -10.330 | -12.450 | -4.933 | 11.313 | |
| Dividend Paid And Capex Coverage Ratio | -3.330 | -10.330 | -12.450 | -4.933 | 11.313 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.207 | -3.725 | -7.715 | -337.845 | 56.494 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 42.5% | ▲1.1% | ▲0.5% |
| Ebit Margin | -40.2% | ▼-10.7% | ▼-18.7% |
| Ebitda Margin | -35.4% | ▼-9.9% | ▼-17.7% |
| Operating Profit Margin | -35.6% | ▼-2.5% | ▼-11.9% |
| Pretax Profit Margin | -41.4% | ▼-11.4% | ▼-19.3% |
| Continuous Operations Profit Margin | -41.5% | ▼-11.8% | ▼-19.5% |
| Net Profit Margin | -41.5% | ▼-11.8% | ▼-19.5% |
| Bottom Line Profit Margin | -41.5% | ▼-11.8% | ▼-19.5% |
| Current Ratio | 1.539 | ▼-0.309 | ▼-1.292 |
| Quick Ratio | 1.194 | ▼-0.165 | ▼-1.169 |
| Solvency Ratio | -0.435 | ▼-0.055 | ▼-0.174 |
| Cash Ratio | 0.551 | ▼-0.238 | ▼-1.140 |
| Price To Earnings Ratio | -4.218 | ▼-0.200 | ▼-23.507 |
| Price To Earnings Growth Ratio | -0.101 | ▼-0.457 | ▲0.133 |
| Forward Price To Earnings Growth Ratio | -0.101 | ▼-0.457 | ▲0.133 |
| Price To Earnings Diluted Ratio | -4.218 | ▼-0.200 | ▼-24.053 |
| Price To Earnings Diluted Growth Ratio | -0.101 | ▼-0.457 | ▲0.138 |
| Price To Book Ratio | 6.346 | ▲4.400 | ▲2.430 |
| Price To Sales Ratio | 1.741 | ▲0.553 | ▼-1.448 |
| Price To Free Cash Flow Ratio | -5.756 | ▼-0.643 | ▲9.845 |
| Price To Operating Cash Flow Ratio | -7.484 | ▼-1.876 | ▲13.344 |
| Debt To Assets Ratio | 0.350 | ▲0.189 | ▲0.185 |
| Debt To Equity Ratio | 1.426 | ▲1.086 | ▲0.977 |
| Debt To Capital Ratio | 0.588 | ▲0.334 | ▲0.337 |
| Long Term Debt To Capital Ratio | 0.450 | ▲0.400 | ▲0.316 |
| Financial Leverage Ratio | 4.069 | ▲1.965 | ▲1.922 |
| Working Capital Turnover Ratio | 2.658 | ▲1.107 | ▲1.192 |
| Operating Cash Flow Ratio | -0.443 | ▼-0.068 | ▼-0.199 |
| Operating Cash Flow Sales Ratio | -0.233 | ▼-0.021 | ▼-0.104 |
| Free Cash Flow Operating Cash Flow Ratio | 1.300 | ▲0.203 | ▲0.182 |
| Debt Service Coverage Ratio | -2.477 | ▼-0.796 | ▼-1.055 |
| Interest Coverage Ratio | -31.852 | ▲58.068 | ▲27.602 |
| Short Term Operating Cash Flow Coverage Ratio | -1.760 | ▼-0.315 | ▼-0.680 |
| Operating Cash Flow Coverage Ratio | -0.595 | ▲0.425 | ▲0.038 |
| Capital Expenditure Coverage Ratio | -3.330 | ▲7.000 | ▲0.616 |
| Dividend Paid And Capex Coverage Ratio | -3.330 | ▲7.000 | ▲0.616 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.207 | ▼-1.481 | ▲54.393 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $123.2M | $82.4M | $195.3M | $366.6M | $192.5M | |
| Enterprise value | $130.4M | $65.9M | $156.7M | $309.3M | $150.2M | |
| EV / Sales | 1.84x | 0.95x | 2.40x | 5.34x | 2.88x | |
| EV / Op. cash flow | -7.92x | -4.49x | -9.88x | -97.31x | 28.58x | |
| EV / Free cash flow | -6.09x | -4.09x | -9.14x | -80.91x | 31.35x | |
| EV / EBITDA | -5.21x | -3.73x | -7.71x | -337.85x | 56.49x | |
| Net debt / EBITDA | -0.29x | 0.93x | 1.90x | 62.66x | -15.90x | |
| Current ratio | 1.54x | 1.85x | 2.84x | 4.17x | 3.75x | |
| Income quality | 0.56x | 0.71x | 0.69x | 1.03x | 6.35x | |
| Graham number | — | — | — | — | $1 | |
| Graham net-net | -$0 | $0 | $1 | $2 | $1 | |
| Tax burden | 100.2% | 99.1% | 101.1% | 109.6% | 253.6% | |
| Interest burden | 102.8% | 101.2% | 101.1% | 106.7% | 84.1% | |
| Working capital | $20.0M | $33.2M | $56.2M | $73.4M | $56.2M | |
| Invested capital | $38.2M | $47.5M | $69.1M | $83.2M | $65.7M | |
| Return on assets | -37.1% | -23.1% | -22.6% | -2.9% | 0.9% | |
| Operating ROA | -30.0% | -24.1% | -21.1% | -5.5% | -4.5% | |
| Return on tangible assets | -39.4% | -24.1% | -23.5% | -2.9% | 1.0% | |
| Return on equity | -151.1% | -48.6% | -36.4% | -4.0% | 1.5% | |
| Return on invested capital | -49.2% | -37.8% | -28.9% | -6.0% | -4.9% | |
| Return on capital employed | -60.2% | -45.9% | -31.3% | -6.3% | -5.2% | |
| Earnings yield | -23.8% | -25.0% | -11.7% | -0.8% | 0.4% | |
| Free cash flow yield | -17.4% | -19.6% | -8.8% | -1.0% | 2.5% | |
| Capex / Op. cash flow | -30.0% | -9.7% | -8.0% | -20.3% | 8.8% | |
| Capex / Depreciation | 144.2% | 50.7% | 61.2% | 37.4% | 20.5% | |
| Capex / Sales | 7.0% | 2.1% | 2.0% | 1.1% | 0.9% | |
| SG&A / Sales | 63.9% | 61.4% | 61.7% | 42.7% | 37.7% | |
| R&D / Sales | 14.3% | 13.1% | 12.6% | 10.4% | 10.8% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 5.9% | 4.1% | 3.8% | 3.1% | 4.1% | |
| Days sales outstanding | 117d | 111d | 119d | 100d | 97d | |
| Days payables outstanding | 106d | 117d | 116d | 80d | 75d | |
| Operating cycle | 232d | 283d | 275d | 242d | 199d | |
| Cash conversion cycle | 126d | 165d | 159d | 162d | 124d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
No employee-count data synced.
Peer market caps
Recent news
- 2026-08-17 Analysts Set FocalTherics (NASDAQ:FOCL) Target Price at $9.00 FocalTherics (NASDAQ: FOCL - Get Free Report) has earned a consensus recommendation of "Hold" from the five analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating
- 2026-08-13 EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript
- 2026-08-13 FocalTherics Q2 Earnings Call Highlights FocalTherics NASDAQ: FOCL reported second-quarter HIFU revenue of $13.2 million, up 39% from $9.5 million a year earlier, as the company continued to expand sales of its Focal One high-intensity focused ultrasound platform for focal therapy.
- 2026-08-13 FocalTherics™ Reports Second Quarter 2026 Financial Results FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial results for the second quarter of 2026. This marks the Company''s first reporting period presenting its HIFU business as continuing operations and its ESWL and Distribution businesses as discontinued operations.
- 2026-08-11 FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic energy-based therapies, announced the pricing of its underwritten public offering of 8,425,000 of American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, €0.13 nominal value per share at a public offering price of $4.75 per ADS, before underwriting discounts and commissions (the “Offering”). All of the ADSs are being sold by the Company.
- 2026-08-11 FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Company''s HIFU segment, reported as continuing operations, for the second quarter of 2026. During the second quarter of 2026, the Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements — Discontinued Operations, and ASC 360-10, Property, Plant, and Equipment, and the Company determined that the planned exit represents a strategic shift that will have a significant effect on the Company''s operations and financial results.
- 2026-08-11 FocalTherics™ Announces Proposed Public Offering of American Depositary Shares FocalTherics™ Announces Proposed Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic energy-based therapies, announced today that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, €0.13 nominal value per share (the “Offering”). All of the ADSs in the proposed Offering will be sold by the Company.
- 2026-08-05 FocalTherics (FOCL) Surges 6.2%: Is This an Indication of Further Gains? FocalTherics (FOCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn''t suggest further strength down the road.
- 2026-07-30 FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026 Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT
- 2026-07-30 FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026 FocalTherics to Announce Second Quarter 2026 Financial Results on August 13, 2026 Company to host conference call and webcast on Thursday, August 13 at 4:30 p. m. EDT AUSTIN, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics (Nasdaq: FOCL) (the "Company"), the global leader in robotic focal therapy, today announced that it will release its financial results for the second quarter ended June 30, 2026, after market close on Thursday, August 13, 2026.